|
Q1 Sales up 35% close to Break-even Result after first-time Consolidation of Fame
aap Implantate AG, a medical technology company listed in the Prime Standard Segment on the Frankfurt Stock Exchange and specialized in biomaterials and implants for trauma and joint re-construction, achieved, consolidated with the first-time incorporated Dutch Fame Medical Group, 35% sales growth the first three months of financial year 2007 to EUR 5.9 million (previ-ous year: EUR 4.4 million) and a slightly negative operating result of EUR 0.1 million (previous year: EUR 0.7 million). As already announced, this trend was due to a sales de¬cline at the “old” aap companies after sales of low-margin merchandise were discontinued and to reduced ship-ments to a large customer.
| In EUR million | Q1/2007 | Q1/2006 | Change on year | | Sales | 5.9 | 4.4 | +35% | | EBITDA | 0.4 | 1.1 | -64% | | EBIT | -0.1 | 0.7 | -116% | | EBT | -0.2 | 0.7 | -129% | | Net period Result | -0.1 | 0.4 | -130% | | Equity (ratio) | 21.5 (37%) | 21.6 (77%) | 0% | | Balance sheet total | 59.0 | 28.0 | +111% | | Employees | 263 | 161 | +63% |
In the first quarter of 2007 the aap Group earned an EBITDA of EUR 0.4 million (previous year: EUR 1.1 million). Group EBIT was EUR minus 0.1 million (previous year: EUR 0.7 million), EBT EUR minus 0.2 million (previous year: EUR 0.7 million). With a EUR 59.0 million (previous year: EUR 28.0 million) balance sheet total the equity ratio is currently 37% because the capital increase has not yet been completed. After the capital increase it would be 72%.
In the first months of financial year 2007 aap entered into distribution cooperations on bioma-terial products with Zimmer and Medtronic, global market leaders in the orthopedic and spinal field. These contracts confirming aap´s successful product strategy and good technological posi-tion and will lead to higher sales from the second half of 2007. For the full year 2007 aap an-ticipates sales growth, including Fame, of more than 60% to around EUR 30 million from EUR 18.6 million in 2006.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
